AVO Aveon Group LP Com USD0.01

Advanced Medical Optics Announces Release Date for Third Quarter 2004 Financial Results SANTA ANA, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) (NYSE:AVO), a global leader in ophthalmic surgical devices and eye care products, today announced it will report third quarter 2004 financial results before market open on Thursday, October 21, 2004. James V. Mazzo, AMO's president and chief executive officer, and Richard A. Meier, corporate vice president and chief financial officer, will host a live webcast to discuss the results on October 21, 2004, at 10:00 a.m. ET. To participate in the live webcast or access the archived replay, please visit AMO's Investors/Media site at http://www.amo-inc.com/. It is AMO's policy to comply fully with Regulation FD. Therefore, AMO intends to utilize this webcast to discuss financially oriented goals and objectives and to disclose material company and industry-based topics in an open manner. The company does not plan to report or comment on its progress during the quarter. Any statement made by others with respect to progress mid-quarter cannot be attributed to the company. During a quarter, the company's commentary will be limited to discussions of public information, such as historic financial performance, and matters that are deemed to be immaterial. AMO will make no comments with respect to market rumors or speculation. About Advanced Medical Optics Advanced Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and marketing of ophthalmic surgical and eye care products. The company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include intraocular lenses, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 2,800 worldwide. The company has operations in about 20 countries and markets products in approximately 60 countries. For more information, visit the company's Web site at http://www.amo-inc.com/. Investors: Erika Richmond (714) 247-8348 DATASOURCE: Advanced Medical Optics, Inc. CONTACT: investors, Erika Richmond of Advanced Medical Optics, Inc., +1-714-247-8348, or Web site: http://www.amo-inc.com/

Copyright